Search Results
Results found for "Fubiao Shi"
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
The metrics shift: k_inact (rate of inactivation) replaces static Ki values. k_inact/KI becomes the
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
Why This Matters: IP-One helped set a new gold standard for functional GPCR assays—shifting how compounds Dual control: not just brightness but fluorescence lifetime, with drastic shifts as pH drops.
- Understanding Enzyme Inhibition In GPCR Discovery Programs
This week —NIH’s new GPCR biosensor push, a leadership shift at Septerna, and a bold thesis on stabilizing You’ll explore how catalytic control, allosteric shifts, and CYP450 behavior rewrite the rules of pharmacology
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
That same shift in mindset (seeing enzymes as predictable, targetable, quantifiable systems ) is exactly Their broad substrate tolerance shields us from xenobiotics.
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
Inside Premium: Key FDA moves reshaping GPCR pipelines, shifting obesity and CNS strategies, and global to explore how computational modeling is evolving from explanation to real prediction — and why that shift
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
By modulating receptor expression or sensitivity, we can shift the “lens” through which drug activity
- Orthosteric vs. Allosteric Interactions: The Silent Decider of Safety and Success
. ✅ Insight into Consequences: How binding sites determine receptor state shifts, signaling outcomes Allosteric sites operate differently: ligands bind elsewhere, transmit energy changes, and shift the This has immediate implications for interpreting EC50 shifts, partial agonism, and assay readouts—especially orthosterically, allosterically, or with mixed mechanisms—and why that matters for interpreting EC₅₀ shifts
- Why Opposing Processes Matter for Your Next GPCR Drug
Some can make a mediocre drug shine. Get a sense of why inverse agonists may be necessary to truly shift the physiological balance.
- The Five Traps of Ignoring Kinetics
Instead of clean monophasic curves, you’ll see biphasic signatures or sequential shifts—first cholinesterase It’s a shift in how expert drug hunters see pharmacology.
- From Snapshots to Predictions: Why Mechanism of Action Matters
A compound shifts the curve. It elevates the baseline. But what does that really mean? Take the example Terry highlights: an agonist curve with a rightward shift and elevated baseline. The shift continues linearly. Allosteric? The shift plateaus once the allosteric site saturates. compound produced four completely different assay signatures depending on the system: Sometimes it shifted It’s a shift in how you approach discovery.
- How a Failed Med School Dream Sparked a GPCR Biotech Revolution
Superluminal is building systems that learn from receptor movement, conformational shifts, and complex emphasizes that building a startup is not simply a continuation of research — it requires a mindset shift
- Understanding the Journey: Catherine Demery's Path to Addiction Science
But something shifted.
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
While writing a literature review on opioid and alcohol addiction susceptibility, something shifted.
- Why “Displacement” Misleads You: Allosteric Binding Demystified
You’ll learn how to recognize these shifts using vivid analogies (like Bruce Wayne vs. model binding with cooperativity factors (α, β, γ, σ) using the Hall allosteric cube The Allosteric Shift It redefines how we interpret radioligand curves , shifts in signal, and the meaning of “inhibition.” Kenakin shows how even small cooperativity values (like α = 0.1) cap the shift in signal .
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
extended fluorescence duration, enable delayed emission readings, have narrow bands and high stokes shift
- Radioligands vs. Fluorescent Ligands: Binding Assays
been used to study GPCRs for decades, but with the advances in the fluorescence field, assays have shifted
- Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells
For example, some assays benefit from using a more red-shifted fluorescent label or a combination of
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
Systems for GPCR Drug Discovery The only way out for GPCR drug discovery programs isn’t more people or shinier
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
Kenakin’s latest lecture delivers a paradigm shift for pharmacologists working on drugs where in vitro
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Why Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you DR curves shift to the right with no loss of maximal effect. One shifts neatly to the right without dropping the maximum.
- Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game
—Alessandro Nicoli A New Era of GPCR Research AlphaFold didn’t just fill a gap—it shifted the focus of
- Unlock the Hidden Lives of Receptors – Are You Ready?
Imagine you're navigating a vast terrain—not on foot, but through the shape-shifting world of GPCRs.
- Understanding Orthosteric Binding: The Key to Drug Action
It’s about a dynamic dance of chemical forces, equilibrium shifts, and molecular decisions that determine
- From GPCR Data Chaos to Decisive Action
I know how to ask the right scientific questions—and when to shift from analysis to execution.
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
But then came the industry shift. “Companies started shutting down neuroscience and GPCR programs.
- What If the Most Important Part of Your Drug Isn’t What It Binds—But What It Does?
some agonists succeed in sensitive tissues but fail elsewhere—and how this knowledge can dramatically shift
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
GPCR-targeted drugs fail—not because of poor chemistry, but because we’ve misunderstood how these shape-shifting
- The Chemistry of Confidence: Aha Moments That Shape Scientific Careers
“The first time I wore my lucky cactus shirt to a major meeting... and it led to a game-changing collaboration
- From Multiplex to Models: Scaling Up GPCR Discovery in the Post-Silo Era
Sakmar reflects on a generational shift in training.
- From One to Many: How a GPCR Curiosity Became a Field-Wide Toolkit
Why It Matters This isn’t just a dataset, it’s a shift in how GPCR biology is approached : Study known






























